HERTFORDSHIRE, England and
PITTSBURGH, April 3, 2019 /PRNewswire/ -- Global
pharmaceutical company Mylan N.V. (NASDAQ:MYL) is committed to
doing its part to achieve a positive, sustained impact on the world
around us, from ensuring responsible operations that provide high
quality medicine in more than 165 countries across developed and
developing markets to continuing to advocate for the 7 billion
patients the company seeks to serve.
As part of that commitment, Mylan today released its Global
Social Responsibility 2018 Progress Report, which provides an
enterprise-wide overview of Mylan's operations as they relate to
various environmental, social and governance (ESG) matters.
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/8094854-mylan-global-social-responsibility-gsr-report/
"As a global healthcare leader, we take seriously the impact we
have on the lives of billions across the world," said Heather Bresch, CEO of Mylan. "Our approach to
sustainability is centered around our mission to improve access to
medicine. This focus dictates that we continuously work to
strengthen and adapt our business model to benefit the patients and
communities we serve today as well as those we envision helping in
the future."
To further enhance Mylan's global social responsibility efforts,
the company undertook its most comprehensive analysis to date to
identify key social responsibility priorities. In addition, Mylan
continued its work around the world to support patients along every
step of their healthcare journey.
"Our commitment to global social responsibility is a fundamental
component of our aspiration to deliver better health for a better
world. It's why many of our initiatives and priorities are directly
aligned with our mission of access," said Lara Ramsburg, head of Global
Sustainability.
2018 Global Social Responsibility Report Highlights
- To date, Mylan has received regulatory approvals for
biosimilars in more than 65 countries, giving us the potential to
provide more affordable alternatives to costly biologic medicines
that treat devastating and debilitating diseases such as cancer,
diabetes and rheumatoid arthritis. Additionally, in 2018 Mylan was
the first to provide a trastuzumab biosimilar in Guatemala, Thailand and Pakistan.
- Procured manufacturing capabilities in South Africa to increase access to life-saving
antiretrovirals (ARV)
- Expanded access to HIV self-tests in low- and middle-income
countries and received tentative FDA approval for first-ever
Lopinavir/Ritonavir 40mg/10mg oral granules, a pediatric-friendly
ARV for HIV-positive infants
- Provided hepatitis B and C treatments for more than 350,000
patients in low- and middle-income countries; developed new
partnerships such as those with the governments of Burkina Faso, Ivory
Coast and Cameroon to
launch hepatitis B and C programs that bundle treatment and
diagnostics, facilitate screening programs and build patient and
provider awareness
- Became the first company to receive World Health Organization
prequalification for flucytosine 500 mg, an orphan drug used for
the treatment of cryptococcal meningitis
- Supported the AMR Industry Alliance's Common Antibiotic
Manufacturing Framework
- Added water security data to our CDP global disclosure
submission
- Increased renewable energy purchases by approximately 30%
- Collaborated with more than 50 organizations worldwide on
issues of global public health
To learn more visit
http://www.mylan.com/en/social-responsibility.
Commitment to the United Nations (U.N.) Global
Compact
Mylan is a signatory to the U.N. Global Compact and is committed to
its 10 principles aimed at protecting human rights and the
environment and ensuring fair labor and corruption-free business
practices. The Global Social Responsibility 2018 Progress Report
constitutes Mylan's Communication on Progress Report.
Support of the Sustainable Development Goals (SDGs)
The Sustainable Development Goals (SDGs), adopted by all U.N.
Member States in 2015, form the basis for collectively creating a
better future by addressing fundamental global challenges such as
poverty, poor health, inequality and climate change, among others.
Mylan supports the agenda and believes that companies can play a
central role in helping to achieve these development goals.
The SDG that is most related to Mylan's mission and impact as a
business is No. 3: Good Health and Well Being. Our broad and
diverse portfolio across ten key therapeutic areas – combined with
our long-standing commitment to increasing access to high quality
medicine through innovation, expansion and partnerships – strongly
positions Mylan to make continued contributions toward this
goal.
About Mylan
Mylan is a global pharmaceutical company committed to setting new
standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 7,500 marketed products around the world,
including antiretroviral therapies on which more than 40% of people
being treated for HIV/AIDS globally depend. We market our products
in more than 165 countries and territories. We are one of the
world's largest producers of active pharmaceutical ingredients.
Every member of our approximately 35,000-strong workforce is
dedicated to creating better health for a better world, one person
at a time. Learn more at Mylan.com. We routinely post information
that may be important to investors on our website at
investor.mylan.com.
View original
content:http://www.prnewswire.com/news-releases/striving-to-create-better-health-for-a-better-world-mylans-global-social-responsibility-2018-progress-report-now-available-300823950.html
SOURCE Mylan N.V.